JP6674028B2 - モノクローナル抗体組成物中のアフコシル化種の調節 - Google Patents

モノクローナル抗体組成物中のアフコシル化種の調節 Download PDF

Info

Publication number
JP6674028B2
JP6674028B2 JP2018535126A JP2018535126A JP6674028B2 JP 6674028 B2 JP6674028 B2 JP 6674028B2 JP 2018535126 A JP2018535126 A JP 2018535126A JP 2018535126 A JP2018535126 A JP 2018535126A JP 6674028 B2 JP6674028 B2 JP 6674028B2
Authority
JP
Japan
Prior art keywords
culture
monoclonal antibody
species
fucose
glycan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018535126A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019500876A5 (enExample
JP2019500876A (ja
Inventor
サントロ マーク
サントロ マーク
ジョン ジョセ ケビン
ジョン ジョセ ケビン
マダブーシ スリ
マダブーシ スリ
ギャングロフ スコット
ギャングロフ スコット
Original Assignee
アウトルック セラピューティクス，インコーポレイティド
アウトルック セラピューティクス，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57944513&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6674028(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アウトルック セラピューティクス，インコーポレイティド, アウトルック セラピューティクス，インコーポレイティド filed Critical アウトルック セラピューティクス，インコーポレイティド
Publication of JP2019500876A publication Critical patent/JP2019500876A/ja
Publication of JP2019500876A5 publication Critical patent/JP2019500876A5/ja
Application granted granted Critical
Publication of JP6674028B2 publication Critical patent/JP6674028B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2018535126A 2016-01-06 2017-01-05 モノクローナル抗体組成物中のアフコシル化種の調節 Active JP6674028B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662275384P 2016-01-06 2016-01-06
US62/275,384 2016-01-06
PCT/US2017/012349 WO2017120347A1 (en) 2016-01-06 2017-01-05 Modulation of afucosylated species in a monoclonal antibody composition

Publications (3)

Publication Number Publication Date
JP2019500876A JP2019500876A (ja) 2019-01-17
JP2019500876A5 JP2019500876A5 (enExample) 2020-02-13
JP6674028B2 true JP6674028B2 (ja) 2020-04-01

Family

ID=57944513

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018535126A Active JP6674028B2 (ja) 2016-01-06 2017-01-05 モノクローナル抗体組成物中のアフコシル化種の調節

Country Status (8)

Country Link
US (1) US20190161543A1 (enExample)
EP (1) EP3400241B1 (enExample)
JP (1) JP6674028B2 (enExample)
CN (1) CN109153716A (enExample)
AU (1) AU2017206006B2 (enExample)
CA (1) CA3010598A1 (enExample)
MX (1) MX2018008447A (enExample)
WO (1) WO2017120347A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014337263B2 (en) 2013-10-16 2019-12-12 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
EP3247718B1 (en) 2015-01-21 2021-09-01 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
EP3411401A1 (en) 2016-02-03 2018-12-12 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
US12325737B2 (en) * 2018-03-26 2025-06-10 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
HU231514B1 (hu) * 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
CA3123591A1 (en) * 2018-12-19 2020-06-25 Seagen Inc. Controlled fucosylation of antibodies
WO2021066772A1 (en) * 2019-10-01 2021-04-08 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Cell culture medium for reducing fucosylation and basic variants in the production of antibodies
US20240141020A1 (en) * 2021-02-12 2024-05-02 Lonza Bend Inc. Method for modulating afucoslyation of an antibody product

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US8227241B2 (en) 2004-03-12 2012-07-24 Unigene Laboratories, Inc. Bacterial host cell for the direct expression of peptides
ATE515566T1 (de) 2005-05-26 2011-07-15 Cytos Biotechnology Ag Skalierbares fermentationsverfahren
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
PL2282773T3 (pl) * 2008-05-02 2014-08-29 Seattle Genetics Inc Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
DK2808393T3 (en) 2009-06-02 2018-03-12 Regeneron Pharma Cells insufficient for fucosylation
WO2010141855A1 (en) * 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
WO2013114165A1 (en) * 2012-01-30 2013-08-08 Dr Reddy's Laboratories Limited Process of obtaining glycoprotein composition with increased afucosylation content
NO2760138T3 (enExample) * 2012-10-01 2018-08-04
WO2015140700A1 (en) * 2014-03-19 2015-09-24 Dr. Reddy's Laboratories Limited Cell culture process
CN108431026B (zh) * 2015-11-02 2023-02-17 豪夫迈·罗氏有限公司 制备岩藻糖基化和去岩藻糖基化形式的蛋白质的方法

Also Published As

Publication number Publication date
JP2019500876A (ja) 2019-01-17
MX2018008447A (es) 2019-05-30
EP3400241B1 (en) 2020-07-22
US20190161543A1 (en) 2019-05-30
CA3010598A1 (en) 2017-07-13
CN109153716A (zh) 2019-01-04
EP3400241A1 (en) 2018-11-14
WO2017120347A1 (en) 2017-07-13
AU2017206006A1 (en) 2018-07-19
AU2017206006B2 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
AU2017206006B2 (en) Modulation of afucosylated species in a monoclonal antibody composition
AU2014288811B2 (en) Improved process for production of monoclonal antibodies
JP2019500878A (ja) モノクローナル抗体組成物中の高分子量種、酸性荷電種、及び断片の低減
TW200914614A (en) Cell culture method using amino acid-enriched medium
JP2019514383A (ja) 細胞培養培地
RU2012121876A (ru) Композиции и способы на основе dac hyp
CN105820248A (zh) 一种新型抗egfr单克隆抗体的制备方法及应用
WO2020229584A1 (en) Method for reducing methionine oxidation in recombinant proteins
WO2017081093A1 (en) Methods for modulating production profiles of recombinant proteins
KR20240096888A (ko) 세포 배양 방법
CN107460221B (zh) 一种降低抗pd-l1抗体中蛋白聚合物的细胞培养方法
WO2017008736A1 (zh) 抗体依赖性细胞介导的细胞毒性增强的奥法木抗体
US11186858B1 (en) Methods for increasing biosimilarity
US20240425894A1 (en) Cell culture processes
KR20160025622A (ko) 단일클론항체의 생산에 대한 개선된 공정
CN118516439A (zh) 一种提高IgG2B型二硫键异构体比例的方法
CN121718485A (zh) 一种调节抗体adcc活性的细胞培养基、试剂盒和方法
HK1138038A (en) Cell culture method using amino acid-enriched medium
CN117616044A (zh) 抗Her3抗体及其应用
HK1224337B (en) Cell culture method using amino acid-enriched medium
AU2015372704A1 (en) A method for controlling glycosylation of recombinant glycoprotein

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191226

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20191226

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20200116

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200305

R150 Certificate of patent or registration of utility model

Ref document number: 6674028

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250